Document is current
Any future updates will be listed below
-
Authors
Baldwin, Grace https://orcid.org/0000-0001-9872-6974
Vingopoulos, Filippos https://orcid.org/0000-0003-3778-5473
Garg, Itika https://orcid.org/0000-0002-9537-8561
Moon, Jade Y.
Zeng, Rebecca
Cui, Ying
Katz, Raviv
Le, Rongrong https://orcid.org/0000-0002-5837-4545
Lu, Edward S.
Sayah, Diane N. https://orcid.org/0000-0002-3734-403X
Hassan, Zakariyya
Kim, Leo A. https://orcid.org/0000-0001-9106-6416
Elze, Tobias https://orcid.org/0000-0002-2032-0496
Husain, Deeba https://orcid.org/0000-0002-8494-0950
Miller, John B. https://orcid.org/0000-0003-0109-9738
- License Information
-
More Information
Article History
Received: 30 September 2022
Revised: 9 April 2023
Accepted: 21 April 2023
First Online: 6 June 2023
Declarations
:
: The study was conducted in accordance with the tenets set forth in the Declaration of Helsinki and all necessary authorizations were obtained from the MEE Institutional Review Board (Protocol #: 2019P001863).
: Written informed consent was obtained from all participants prior to the inclusion in this study.
: L.A.K. has received research support from the National Eye Institute (R01EY027739), CureVac AG, and INGENIA Therapeutics and has a financial arrangement with Pykus Therapeutics. D.H. is a consultant for Allergen, Genentech, and Omeicos Therapeutics and has received financial support from National Eye Institute, Lions VisionGift, Commonwealth Grant, Lions International, Syneos LLC, and the Macular Society. J.B.M. is a consultant for Alcon, Allergan, Topcon, Carl Zeiss, Sunovion, and Genentech.
: The funding organization had no role in design or conduct of this research.
